| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Critical Care | 19 | 2018 | 647 | 1.890 |
Why?
|
| Pregnancy Complications | 9 | 2018 | 503 | 1.670 |
Why?
|
| Critical Illness | 9 | 2021 | 588 | 1.280 |
Why?
|
| Respiration, Artificial | 14 | 2021 | 452 | 1.280 |
Why?
|
| Asthma | 12 | 2008 | 743 | 1.140 |
Why?
|
| Intensive Care Units | 14 | 2016 | 475 | 1.120 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 6 | 2017 | 594 | 0.750 |
Why?
|
| Burnout, Professional | 2 | 2018 | 114 | 0.640 |
Why?
|
| Snoring | 1 | 2018 | 15 | 0.630 |
Why?
|
| Sepsis | 6 | 2021 | 472 | 0.630 |
Why?
|
| Nursing Staff, Hospital | 3 | 2018 | 60 | 0.610 |
Why?
|
| Job Satisfaction | 1 | 2018 | 77 | 0.580 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2018 | 74 | 0.580 |
Why?
|
| Plant Poisoning | 1 | 2016 | 1 | 0.540 |
Why?
|
| Euphorbiaceae | 1 | 2016 | 2 | 0.540 |
Why?
|
| Lactoferrin | 2 | 2015 | 76 | 0.530 |
Why?
|
| Hypokalemia | 1 | 2016 | 41 | 0.530 |
Why?
|
| Pregnancy Complications, Cardiovascular | 3 | 2015 | 103 | 0.530 |
Why?
|
| Disease Management | 2 | 2017 | 511 | 0.500 |
Why?
|
| Endocrine System Diseases | 2 | 2006 | 37 | 0.500 |
Why?
|
| Respiratory Insufficiency | 5 | 2017 | 234 | 0.490 |
Why?
|
| Helium | 2 | 2005 | 10 | 0.470 |
Why?
|
| Respiratory Function Tests | 6 | 2021 | 194 | 0.460 |
Why?
|
| Postpartum Period | 1 | 2015 | 206 | 0.460 |
Why?
|
| Infertility | 2 | 2006 | 90 | 0.450 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2014 | 30 | 0.450 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 141 | 0.440 |
Why?
|
| Bronchodilator Agents | 3 | 2005 | 153 | 0.440 |
Why?
|
| India | 8 | 2016 | 218 | 0.430 |
Why?
|
| Plasma Exchange | 1 | 2014 | 83 | 0.430 |
Why?
|
| Stress, Psychological | 1 | 2018 | 555 | 0.430 |
Why?
|
| Delivery, Obstetric | 1 | 2015 | 253 | 0.420 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2016 | 457 | 0.410 |
Why?
|
| Female | 56 | 2022 | 64882 | 0.400 |
Why?
|
| Humans | 93 | 2022 | 122293 | 0.390 |
Why?
|
| Physicians | 2 | 2018 | 582 | 0.380 |
Why?
|
| Oxygen | 4 | 2005 | 549 | 0.380 |
Why?
|
| Glucocorticoids | 1 | 2014 | 379 | 0.380 |
Why?
|
| Adult | 39 | 2021 | 28732 | 0.370 |
Why?
|
| Smoking | 4 | 2006 | 1028 | 0.360 |
Why?
|
| Shock, Septic | 7 | 2015 | 148 | 0.360 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2022 | 112 | 0.350 |
Why?
|
| Acute Kidney Injury | 2 | 2016 | 606 | 0.340 |
Why?
|
| Pregnancy | 13 | 2020 | 7092 | 0.340 |
Why?
|
| Lung Diseases | 3 | 2010 | 384 | 0.320 |
Why?
|
| Pneumocystis | 3 | 1997 | 11 | 0.310 |
Why?
|
| Respiratory Sounds | 1 | 2008 | 68 | 0.310 |
Why?
|
| Global Health | 2 | 2010 | 555 | 0.300 |
Why?
|
| Middle Aged | 35 | 2022 | 25639 | 0.300 |
Why?
|
| Health Promotion | 1 | 2010 | 385 | 0.290 |
Why?
|
| Vocal Cords | 2 | 2006 | 63 | 0.280 |
Why?
|
| Vasodilator Agents | 3 | 2017 | 203 | 0.280 |
Why?
|
| Hypoxia | 2 | 2020 | 246 | 0.280 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 635 | 0.280 |
Why?
|
| Lung Diseases, Obstructive | 2 | 1998 | 34 | 0.270 |
Why?
|
| Nervous System Diseases | 2 | 2012 | 367 | 0.270 |
Why?
|
| Aerosol Propellants | 1 | 2005 | 2 | 0.260 |
Why?
|
| Male | 40 | 2022 | 59520 | 0.250 |
Why?
|
| Albuterol | 1 | 2005 | 52 | 0.250 |
Why?
|
| Nitric Oxide | 3 | 2009 | 438 | 0.250 |
Why?
|
| Tobacco Use Disorder | 1 | 2006 | 87 | 0.250 |
Why?
|
| Withholding Treatment | 1 | 2005 | 67 | 0.240 |
Why?
|
| Hypnotics and Sedatives | 2 | 2021 | 134 | 0.240 |
Why?
|
| Family Health | 1 | 2005 | 258 | 0.240 |
Why?
|
| Metabolic Diseases | 1 | 2006 | 128 | 0.230 |
Why?
|
| Terminal Care | 1 | 2005 | 114 | 0.230 |
Why?
|
| Pneumonia, Pneumocystis | 4 | 1997 | 37 | 0.220 |
Why?
|
| Skin Diseases | 1 | 2004 | 122 | 0.220 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2006 | 250 | 0.210 |
Why?
|
| Ipratropium | 1 | 2002 | 7 | 0.210 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2004 | 147 | 0.210 |
Why?
|
| Hospitalization | 4 | 2022 | 1727 | 0.190 |
Why?
|
| Internal Medicine | 2 | 2008 | 147 | 0.190 |
Why?
|
| Prospective Studies | 10 | 2014 | 5963 | 0.190 |
Why?
|
| Aged | 21 | 2022 | 18784 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 1679 | 0.190 |
Why?
|
| Lung Transplantation | 2 | 2022 | 316 | 0.180 |
Why?
|
| Carbon Dioxide | 5 | 2009 | 274 | 0.180 |
Why?
|
| Propofol | 1 | 2021 | 44 | 0.180 |
Why?
|
| Gastrointestinal Diseases | 1 | 2004 | 335 | 0.180 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2014 | 195 | 0.180 |
Why?
|
| Emigrants and Immigrants | 1 | 2022 | 148 | 0.180 |
Why?
|
| Acute Disease | 6 | 2017 | 1090 | 0.180 |
Why?
|
| Fluorescent Antibody Technique, Direct | 2 | 1997 | 12 | 0.180 |
Why?
|
| Dexmedetomidine | 1 | 2021 | 44 | 0.180 |
Why?
|
| Conscious Sedation | 1 | 2021 | 62 | 0.180 |
Why?
|
| Prone Position | 1 | 2020 | 32 | 0.180 |
Why?
|
| Guideline Adherence | 2 | 2021 | 376 | 0.170 |
Why?
|
| Health Services Accessibility | 1 | 2005 | 581 | 0.170 |
Why?
|
| Double-Blind Method | 6 | 2021 | 1568 | 0.170 |
Why?
|
| Pregnancy Outcome | 4 | 2014 | 592 | 0.170 |
Why?
|
| Algorithms | 4 | 2020 | 1575 | 0.170 |
Why?
|
| Patient Positioning | 1 | 2020 | 54 | 0.170 |
Why?
|
| Bronchi | 3 | 2005 | 100 | 0.170 |
Why?
|
| Positive-Pressure Respiration | 7 | 2020 | 83 | 0.170 |
Why?
|
| Heat Stress Disorders | 1 | 1999 | 10 | 0.160 |
Why?
|
| Risk Adjustment | 1 | 1999 | 58 | 0.160 |
Why?
|
| Risk Factors | 11 | 2014 | 9902 | 0.160 |
Why?
|
| Vibration | 2 | 2008 | 31 | 0.160 |
Why?
|
| Infusions, Parenteral | 2 | 2013 | 100 | 0.160 |
Why?
|
| APACHE | 3 | 2015 | 52 | 0.160 |
Why?
|
| Spirometry | 3 | 2006 | 74 | 0.160 |
Why?
|
| Registries | 2 | 2022 | 1367 | 0.160 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 2817 | 0.150 |
Why?
|
| Diagnosis, Differential | 7 | 2017 | 1871 | 0.150 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2008 | 92 | 0.150 |
Why?
|
| Bronchial Hyperreactivity | 2 | 1996 | 40 | 0.150 |
Why?
|
| Breathing Exercises | 1 | 2017 | 7 | 0.150 |
Why?
|
| Prognosis | 7 | 2011 | 4488 | 0.150 |
Why?
|
| Benzenesulfonates | 1 | 1997 | 11 | 0.150 |
Why?
|
| Yoga | 1 | 2017 | 12 | 0.140 |
Why?
|
| Lung | 7 | 2020 | 1476 | 0.140 |
Why?
|
| Angioedema | 1 | 1997 | 22 | 0.140 |
Why?
|
| Pulmonary Ventilation | 1 | 1997 | 28 | 0.140 |
Why?
|
| Noninvasive Ventilation | 1 | 2017 | 31 | 0.140 |
Why?
|
| Prevalence | 6 | 2014 | 2371 | 0.140 |
Why?
|
| Exercise Tolerance | 1 | 2017 | 72 | 0.140 |
Why?
|
| Fluid Therapy | 1 | 2017 | 120 | 0.140 |
Why?
|
| Equipment Design | 2 | 2008 | 596 | 0.140 |
Why?
|
| Respiratory Tract Diseases | 1 | 1997 | 77 | 0.140 |
Why?
|
| Program Evaluation | 2 | 2010 | 445 | 0.130 |
Why?
|
| Nitric Oxide Synthase | 3 | 2004 | 186 | 0.130 |
Why?
|
| Arginine | 2 | 2009 | 302 | 0.130 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1997 | 210 | 0.130 |
Why?
|
| Medical Staff, Hospital | 1 | 1996 | 92 | 0.130 |
Why?
|
| Fluorescent Dyes | 1 | 1997 | 261 | 0.130 |
Why?
|
| Hospital Mortality | 4 | 2013 | 995 | 0.130 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2014 | 71 | 0.130 |
Why?
|
| Sputum | 1 | 1996 | 110 | 0.120 |
Why?
|
| Specimen Handling | 1 | 1996 | 137 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 231 | 0.120 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1996 | 139 | 0.120 |
Why?
|
| Isoniazid | 1 | 1995 | 70 | 0.120 |
Why?
|
| Hypotension | 2 | 2007 | 177 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 360 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 378 | 0.120 |
Why?
|
| Trachea | 3 | 1997 | 197 | 0.120 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 254 | 0.110 |
Why?
|
| Cerebrospinal Fluid | 1 | 2014 | 93 | 0.110 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2014 | 50 | 0.110 |
Why?
|
| Contrast Media | 1 | 1997 | 459 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 2 | 2012 | 262 | 0.110 |
Why?
|
| Patient Education as Topic | 2 | 1996 | 438 | 0.110 |
Why?
|
| Administration, Inhalation | 3 | 2005 | 177 | 0.110 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2014 | 147 | 0.110 |
Why?
|
| Nebulizers and Vaporizers | 1 | 1993 | 53 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2014 | 176 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2015 | 266 | 0.100 |
Why?
|
| Adolescent | 9 | 2016 | 18940 | 0.100 |
Why?
|
| Placebos | 1 | 2013 | 239 | 0.100 |
Why?
|
| Intubation, Intratracheal | 3 | 1997 | 289 | 0.100 |
Why?
|
| Antitubercular Agents | 1 | 1995 | 343 | 0.100 |
Why?
|
| omega-N-Methylarginine | 2 | 2004 | 12 | 0.100 |
Why?
|
| Pre-Eclampsia | 1 | 2014 | 220 | 0.100 |
Why?
|
| Postoperative Care | 4 | 1988 | 291 | 0.100 |
Why?
|
| High-Frequency Jet Ventilation | 2 | 1988 | 3 | 0.090 |
Why?
|
| Suction | 2 | 1997 | 57 | 0.090 |
Why?
|
| Survival Analysis | 4 | 2010 | 1468 | 0.090 |
Why?
|
| Pneumonia, Lipid | 1 | 1991 | 1 | 0.090 |
Why?
|
| Societies, Medical | 2 | 2010 | 673 | 0.090 |
Why?
|
| Lung Volume Measurements | 2 | 2005 | 67 | 0.090 |
Why?
|
| Treatment Outcome | 7 | 2013 | 12044 | 0.090 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2010 | 36 | 0.090 |
Why?
|
| Decision Trees | 2 | 2004 | 48 | 0.090 |
Why?
|
| Laryngoscopy | 2 | 2006 | 149 | 0.090 |
Why?
|
| Ibuprofen | 1 | 2010 | 41 | 0.090 |
Why?
|
| Amikacin | 1 | 2009 | 24 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 1370 | 0.080 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2009 | 85 | 0.080 |
Why?
|
| Forecasting | 1 | 2010 | 355 | 0.080 |
Why?
|
| Aerosols | 3 | 2009 | 66 | 0.080 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2008 | 32 | 0.080 |
Why?
|
| Citrulline | 1 | 2009 | 84 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 3301 | 0.080 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2008 | 6 | 0.080 |
Why?
|
| Lung Neoplasms | 3 | 2010 | 1614 | 0.080 |
Why?
|
| United States | 7 | 2010 | 10487 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 303 | 0.070 |
Why?
|
| Fever | 1 | 2010 | 295 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 252 | 0.070 |
Why?
|
| Monitoring, Physiologic | 3 | 2005 | 357 | 0.070 |
Why?
|
| Surveys and Questionnaires | 5 | 2022 | 3626 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2010 | 391 | 0.070 |
Why?
|
| Incidence | 3 | 2006 | 3018 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 1990 | 172 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2022 | 15853 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1084 | 0.070 |
Why?
|
| Equipment Failure | 2 | 1984 | 122 | 0.070 |
Why?
|
| Radionuclide Imaging | 2 | 2005 | 151 | 0.070 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 1996 | 157 | 0.070 |
Why?
|
| Laryngeal Diseases | 2 | 1997 | 30 | 0.070 |
Why?
|
| Cross Infection | 1 | 2009 | 331 | 0.070 |
Why?
|
| Young Adult | 3 | 2014 | 8760 | 0.070 |
Why?
|
| Glottis | 1 | 2006 | 31 | 0.070 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2005 | 9 | 0.060 |
Why?
|
| Receptors, Leukotriene | 1 | 2005 | 6 | 0.060 |
Why?
|
| Hospitals, Public | 1 | 2005 | 38 | 0.060 |
Why?
|
| Biological Availability | 1 | 2005 | 128 | 0.060 |
Why?
|
| Mucous Membrane | 1 | 2005 | 82 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 2 | 2004 | 138 | 0.060 |
Why?
|
| Airway Resistance | 1 | 2005 | 36 | 0.060 |
Why?
|
| Central Venous Pressure | 1 | 2005 | 25 | 0.060 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2005 | 50 | 0.060 |
Why?
|
| Professional-Family Relations | 1 | 2005 | 95 | 0.060 |
Why?
|
| Referral and Consultation | 2 | 2021 | 525 | 0.060 |
Why?
|
| Airway Obstruction | 2 | 1997 | 165 | 0.060 |
Why?
|
| Hemodynamics | 7 | 2004 | 838 | 0.060 |
Why?
|
| Blood Pressure Determination | 1 | 2005 | 105 | 0.060 |
Why?
|
| Phosphorus | 1 | 1984 | 55 | 0.060 |
Why?
|
| Leukocytes | 1 | 2005 | 204 | 0.060 |
Why?
|
| Hyperthermia, Induced | 1 | 1984 | 45 | 0.060 |
Why?
|
| Tuberculosis | 1 | 2010 | 569 | 0.060 |
Why?
|
| Pulmonary Edema | 1 | 1984 | 51 | 0.060 |
Why?
|
| Observer Variation | 1 | 2005 | 297 | 0.060 |
Why?
|
| Analgesics, Opioid | 1 | 2008 | 397 | 0.060 |
Why?
|
| Multiple Organ Failure | 1 | 2005 | 140 | 0.060 |
Why?
|
| Pandemics | 2 | 2022 | 1102 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2014 | 3307 | 0.060 |
Why?
|
| Tidal Volume | 2 | 2017 | 36 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2002 | 304 | 0.050 |
Why?
|
| Lung Injury | 1 | 2005 | 118 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 230 | 0.050 |
Why?
|
| Polysomnography | 2 | 2014 | 133 | 0.050 |
Why?
|
| Iron-Dextran Complex | 1 | 1982 | 3 | 0.050 |
Why?
|
| Hydroxyethyl Starch Derivatives | 1 | 1982 | 8 | 0.050 |
Why?
|
| Cardiovascular System | 1 | 2004 | 99 | 0.050 |
Why?
|
| Internship and Residency | 2 | 2008 | 1153 | 0.050 |
Why?
|
| Starch | 1 | 1982 | 25 | 0.050 |
Why?
|
| Brain Death | 1 | 1983 | 55 | 0.050 |
Why?
|
| Developing Countries | 1 | 2004 | 270 | 0.050 |
Why?
|
| Respiratory Therapy | 2 | 2011 | 22 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 1990 | 861 | 0.050 |
Why?
|
| Shock, Hemorrhagic | 1 | 1982 | 50 | 0.050 |
Why?
|
| Respiration | 2 | 1996 | 123 | 0.050 |
Why?
|
| Physical Examination | 2 | 2011 | 163 | 0.050 |
Why?
|
| Gestational Age | 1 | 2005 | 1115 | 0.050 |
Why?
|
| Communication | 1 | 2005 | 505 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 1982 | 323 | 0.050 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2021 | 92 | 0.050 |
Why?
|
| Infusions, Intravenous | 4 | 2010 | 539 | 0.050 |
Why?
|
| Caregivers | 1 | 2005 | 561 | 0.040 |
Why?
|
| Ventilator Weaning | 1 | 2000 | 23 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 2 | 1997 | 315 | 0.040 |
Why?
|
| Disease Progression | 1 | 2006 | 1990 | 0.040 |
Why?
|
| Emergency Service, Hospital | 2 | 1997 | 1060 | 0.040 |
Why?
|
| Heat Stroke | 1 | 1999 | 4 | 0.040 |
Why?
|
| Acclimatization | 1 | 1999 | 15 | 0.040 |
Why?
|
| Body Temperature Regulation | 1 | 1999 | 24 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2000 | 84 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 1997 | 356 | 0.040 |
Why?
|
| International Cooperation | 1 | 1999 | 160 | 0.040 |
Why?
|
| Respiratory Mechanics | 1 | 1998 | 75 | 0.040 |
Why?
|
| Hemoptysis | 2 | 1995 | 22 | 0.040 |
Why?
|
| Electroencephalography | 1 | 1983 | 847 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 1008 | 0.040 |
Why?
|
| Leucine | 2 | 2009 | 309 | 0.040 |
Why?
|
| Time Factors | 4 | 1999 | 6182 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2005 | 1520 | 0.040 |
Why?
|
| Rhinoscleroma | 1 | 1997 | 4 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 1995 | 424 | 0.030 |
Why?
|
| Child | 7 | 2003 | 24063 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 289 | 0.030 |
Why?
|
| Fatty Alcohols | 1 | 1996 | 5 | 0.030 |
Why?
|
| Phosphorylcholine | 1 | 1996 | 26 | 0.030 |
Why?
|
| Asthma, Exercise-Induced | 1 | 1996 | 1 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 5013 | 0.030 |
Why?
|
| Fixatives | 1 | 1996 | 14 | 0.030 |
Why?
|
| Climate | 1 | 1996 | 20 | 0.030 |
Why?
|
| Pulmonary Surfactants | 1 | 1996 | 43 | 0.030 |
Why?
|
| Skin | 1 | 1999 | 503 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 1997 | 237 | 0.030 |
Why?
|
| Cognition | 1 | 2021 | 732 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 582 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 1998 | 263 | 0.030 |
Why?
|
| Vocal Cord Paralysis | 1 | 1997 | 68 | 0.030 |
Why?
|
| Fetal Monitoring | 1 | 1996 | 57 | 0.030 |
Why?
|
| Pyridoxine | 1 | 1995 | 14 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1997 | 226 | 0.030 |
Why?
|
| Famotidine | 1 | 1995 | 9 | 0.030 |
Why?
|
| Career Choice | 1 | 1996 | 143 | 0.030 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 1995 | 40 | 0.030 |
Why?
|
| Gastric Acid | 1 | 1995 | 50 | 0.030 |
Why?
|
| Bronchiectasis | 1 | 1995 | 23 | 0.030 |
Why?
|
| Drug Overdose | 1 | 1995 | 65 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 1996 | 217 | 0.030 |
Why?
|
| Takayasu Arteritis | 1 | 1994 | 13 | 0.030 |
Why?
|
| Hydrostatic Pressure | 2 | 2005 | 8 | 0.030 |
Why?
|
| Patient Selection | 1 | 1998 | 685 | 0.030 |
Why?
|
| Acidosis | 1 | 1995 | 92 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1995 | 461 | 0.030 |
Why?
|
| Social Support | 1 | 1996 | 341 | 0.030 |
Why?
|
| Medical History Taking | 1 | 1994 | 106 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 1996 | 2010 | 0.030 |
Why?
|
| Cardiac Output | 2 | 2004 | 169 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 2796 | 0.030 |
Why?
|
| Bed Occupancy | 1 | 1993 | 3 | 0.030 |
Why?
|
| Respiratory Therapy Department, Hospital | 1 | 1993 | 1 | 0.030 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1993 | 15 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1997 | 339 | 0.030 |
Why?
|
| Amiodarone | 1 | 1993 | 45 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1993 | 70 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2005 | 8096 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 2 | 2006 | 480 | 0.030 |
Why?
|
| Radiography | 2 | 1993 | 804 | 0.020 |
Why?
|
| Mineral Oil | 1 | 1991 | 4 | 0.020 |
Why?
|
| Self Medication | 1 | 1991 | 23 | 0.020 |
Why?
|
| Life Support Care | 1 | 2011 | 45 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2009 | 3229 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1244 | 0.020 |
Why?
|
| Airway Management | 1 | 2011 | 66 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 1991 | 117 | 0.020 |
Why?
|
| Intubation | 1 | 2009 | 18 | 0.020 |
Why?
|
| Seizures | 1 | 1995 | 867 | 0.020 |
Why?
|
| Shock | 1 | 2011 | 89 | 0.020 |
Why?
|
| Constipation | 1 | 1991 | 113 | 0.020 |
Why?
|
| Carbon Isotopes | 1 | 2009 | 272 | 0.020 |
Why?
|
| Texas | 2 | 1998 | 3528 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2080 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 2 | 1987 | 259 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2011 | 340 | 0.020 |
Why?
|
| Mass Screening | 1 | 2014 | 778 | 0.020 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2008 | 78 | 0.020 |
Why?
|
| Pressure | 1 | 1988 | 128 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2011 | 380 | 0.020 |
Why?
|
| Workload | 1 | 2008 | 146 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 194 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1315 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 6290 | 0.020 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2011 | 312 | 0.020 |
Why?
|
| Nitrogen Isotopes | 1 | 2006 | 54 | 0.020 |
Why?
|
| Nitrates | 1 | 2006 | 27 | 0.020 |
Why?
|
| Nitrites | 1 | 2006 | 45 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 2011 | 475 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 1992 | 2997 | 0.020 |
Why?
|
| Length of Stay | 2 | 2007 | 1272 | 0.020 |
Why?
|
| RNA Probes | 1 | 2005 | 30 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2005 | 47 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2008 | 4643 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 268 | 0.020 |
Why?
|
| Mast Cells | 1 | 2005 | 75 | 0.020 |
Why?
|
| Transducers | 1 | 2005 | 25 | 0.020 |
Why?
|
| Homeostasis | 1 | 2009 | 680 | 0.020 |
Why?
|
| Intermittent Positive-Pressure Ventilation | 1 | 1984 | 9 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 2005 | 169 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 474 | 0.010 |
Why?
|
| Glucose | 1 | 2009 | 875 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2005 | 333 | 0.010 |
Why?
|
| Inservice Training | 1 | 2005 | 55 | 0.010 |
Why?
|
| Bloodletting | 1 | 1984 | 4 | 0.010 |
Why?
|
| Eosinophils | 1 | 2005 | 120 | 0.010 |
Why?
|
| Tourniquets | 1 | 1984 | 10 | 0.010 |
Why?
|
| Electrolytes | 1 | 1984 | 51 | 0.010 |
Why?
|
| Osmotic Pressure | 1 | 1984 | 22 | 0.010 |
Why?
|
| Bicarbonates | 1 | 1984 | 98 | 0.010 |
Why?
|
| Nitroglycerin | 1 | 1984 | 23 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 1984 | 29 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2005 | 117 | 0.010 |
Why?
|
| Nitroprusside | 1 | 1984 | 46 | 0.010 |
Why?
|
| Dobutamine | 1 | 1984 | 56 | 0.010 |
Why?
|
| Digoxin | 1 | 1984 | 43 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1997 | 13777 | 0.010 |
Why?
|
| Capillary Permeability | 1 | 1984 | 78 | 0.010 |
Why?
|
| Morphine | 1 | 1984 | 88 | 0.010 |
Why?
|
| Body Weight | 1 | 1988 | 963 | 0.010 |
Why?
|
| Renin | 1 | 1983 | 89 | 0.010 |
Why?
|
| Proteins | 1 | 2009 | 1043 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 1034 | 0.010 |
Why?
|
| Posture | 1 | 1984 | 152 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 319 | 0.010 |
Why?
|
| Diuretics | 1 | 1984 | 158 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 1772 | 0.010 |
Why?
|
| Neutrophils | 1 | 2005 | 371 | 0.010 |
Why?
|
| Pulmonary Circulation | 1 | 2004 | 120 | 0.010 |
Why?
|
| Basement Membrane | 1 | 2003 | 46 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 208 | 0.010 |
Why?
|
| HIV Infections | 1 | 1995 | 1858 | 0.010 |
Why?
|
| Hospital Bed Capacity | 2 | 1993 | 24 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 1990 | 841 | 0.010 |
Why?
|
| Emergencies | 1 | 1984 | 175 | 0.010 |
Why?
|
| Anemia, Hypochromic | 1 | 1982 | 8 | 0.010 |
Why?
|
| Christianity | 1 | 1982 | 14 | 0.010 |
Why?
|
| Dopamine | 1 | 1984 | 273 | 0.010 |
Why?
|
| Oxygen Consumption | 2 | 1999 | 303 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2005 | 517 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 873 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 698 | 0.010 |
Why?
|
| Bronchial Fistula | 1 | 1982 | 21 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 729 | 0.010 |
Why?
|
| Pleural Diseases | 1 | 1982 | 28 | 0.010 |
Why?
|
| Intubation, Gastrointestinal | 1 | 1982 | 52 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 2003 | 155 | 0.010 |
Why?
|
| Fistula | 1 | 1982 | 50 | 0.010 |
Why?
|
| Biopsy | 1 | 2005 | 1246 | 0.010 |
Why?
|
| Macrophages | 1 | 2005 | 611 | 0.010 |
Why?
|
| Pneumothorax | 1 | 1982 | 82 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1984 | 482 | 0.010 |
Why?
|
| Coronaviridae | 1 | 1998 | 4 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 1999 | 81 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 2826 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1999 | 142 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1984 | 1314 | 0.010 |
Why?
|
| Urban Health | 1 | 1998 | 71 | 0.010 |
Why?
|
| Rhinovirus | 1 | 1998 | 59 | 0.010 |
Why?
|
| Orthomyxoviridae | 1 | 1998 | 50 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 2385 | 0.010 |
Why?
|
| Area Under Curve | 1 | 1999 | 307 | 0.010 |
Why?
|
| DNA Primers | 1 | 1998 | 668 | 0.010 |
Why?
|
| Technology Transfer | 1 | 1997 | 8 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1998 | 492 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 1678 | 0.010 |
Why?
|
| Kidney | 1 | 1983 | 1340 | 0.010 |
Why?
|
| Age Factors | 2 | 1994 | 2777 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1998 | 1296 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1996 | 266 | 0.010 |
Why?
|
| History, 20th Century | 1 | 1997 | 384 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1996 | 336 | 0.010 |
Why?
|
| Tissue Fixation | 1 | 1995 | 35 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1998 | 1283 | 0.010 |
Why?
|
| Ventilators, Mechanical | 2 | 1984 | 32 | 0.010 |
Why?
|
| Peptic Ulcer | 1 | 1995 | 145 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1994 | 158 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1995 | 186 | 0.010 |
Why?
|
| Macrophages, Alveolar | 1 | 1993 | 44 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 1995 | 265 | 0.010 |
Why?
|
| Resuscitation Orders | 1 | 1993 | 32 | 0.010 |
Why?
|
| American Hospital Association | 1 | 1992 | 3 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1998 | 1131 | 0.010 |
Why?
|
| Orchiectomy | 1 | 1992 | 46 | 0.010 |
Why?
|
| Patient Transfer | 1 | 1993 | 101 | 0.010 |
Why?
|
| Allied Health Personnel | 1 | 1992 | 74 | 0.010 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1992 | 91 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 1992 | 157 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1992 | 116 | 0.010 |
Why?
|
| Survival Rate | 1 | 1996 | 1997 | 0.010 |
Why?
|
| Testicular Neoplasms | 1 | 1992 | 139 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1994 | 1247 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1994 | 1227 | 0.010 |
Why?
|
| Neoplasms | 1 | 1984 | 2753 | 0.010 |
Why?
|
| Random Allocation | 1 | 1987 | 417 | 0.000 |
Why?
|
| Phenotype | 1 | 1995 | 4151 | 0.000 |
Why?
|
| Vascular Resistance | 1 | 1984 | 189 | 0.000 |
Why?
|
| Postoperative Period | 1 | 1984 | 330 | 0.000 |
Why?
|
| Kidney Function Tests | 1 | 1983 | 126 | 0.000 |
Why?
|
| Infant | 1 | 1993 | 12302 | 0.000 |
Why?
|